Cancer therapy
AssigneeProkarium Limited
InventorsLivija Deban, Hyam Levitsky
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of cancer therapy. In particular, the present invention relates to a live attenuated Gram-negative bacterium for use in the treatment, reduction, inhibition or control of a neoplastic disease in a subject undergoing or intended to undergo immunotherapy with a checkpoint inhibitor therapy, an adoptive T cell therapy and/or an allogeneic or an autologous CAR-T therapy simultaneously, separately or sequentially with the administration of the live attenuated Gram-negative bacterium.
Claims15
A method of treating, inhibiting or controlling a malignant tumor in a subject, wherein the method comprising simultaneously, separately or sequentially administering to the subject, (i) a live attenuated Salmonella bacterium, wherein said live attenuated Salmonella bacterium is orally administered, and (ii) an adoptive T cell therapy or an allogeneic or autologous CAR T-cell therapy, wherein said method results in an enhanced therapeutic efficacy relative to the administration of the live attenuated Salmonella bacterium or adoptive T cell therapy or allogeneic or autologous CAR T-cell therapy alone, wherein said live attenuated Salmonella bacterium is non-recombinant or does not comprise eukaryotic heterologous DNA encoding a therapeutic protein.
Dependencies are inferred from the claim text.